At Aspeya, we want to make a positive difference to people’s lives. We’re harnessing deep insight and scientific expertise to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. Aspeya operates as a separate company under the ownership of Philip Morris International and benefits from access to the oral technology platform of Fertin Pharma, a contract development and manufacturing organization (CDMO) that is a wholly owned subsidiary of Aspeya. Fertin Pharma develops and manufactures innovative oral and intra-oral delivery systems. We’re applying our expertise to innovate in the field of wellness and healthcare in four areas of focus: Cannabinoids Inhaled therapeutics Nicotine replacement therapy (NRT) Consumer health